Sanofi and GSK Receive European Commission Approval for VidPrevtyn Beta COVID-19 Booster
Sanofi and GSK have received European Commission approval for VidPrevtyn Beta, their adjuvanted protein-based COVID-19 booster vaccine. The vaccine is authorized for use as a booster in adults who have completed a primary COVID-19 vaccination series, offering an additional option for protection against multiple SARS-CoV-2 variants.
- Published date: 18-07-2026 10:01 AM
The European Commission has granted marketing authorization to Sanofi and GSK for VidPrevtyn Beta, an adjuvanted protein-based COVID-19 booster vaccine. This approval follows a positive opinion from the European Medicines Agency (EMA) and is based on data demonstrating the vaccine's efficacy as a booster against multiple SARS-CoV-2 variants.
VidPrevtyn Beta is indicated for use as a booster in adults who have previously completed a primary COVID-19 vaccination series. The vaccine leverages a beta variant antigen and GSK's pandemic adjuvant technology, aiming to broaden immune response against circulating variants.
This development provides healthcare professionals across Europe with an additional option for COVID-19 booster vaccination, supporting ongoing public health efforts to manage the pandemic. For more information, visit Sanofi's official announcement.
Sanofi and GSK have received European Commission approval for VidPrevtyn Beta, their adjuvanted protein-based COVID-19 booster vaccine. The vaccine is authorized for use as a booster in adults who have completed a primary COVID-19 vaccination series, offering an additional option for protection against multiple SARS-CoV-2 variants.